The Food and Drug Administration last week reissued its emergency use authorization for the Abbott ID NOW COVID-19 test to indicate that the product is intended for specimens collected “from individuals who are suspected of COVID-19 by their health care provider within the first seven days of the onset of symptoms.” 

The revised EUA also clarifies that the test is authorized for emergency use by laboratories certified under the Clinical Laboratory Improvement Amendments that meet the requirements to perform high, moderate or waived complexity tests; and that U.S. testing facilities must report all results to the appropriate public health authorities.

Related News Articles

Headline
Learn how Loyola University Health System’s pop-up COVID-19 testing laboratory broadened collaboration between clinicians and hospital leadership, improved…
Headline
A recent op-ed in the online publication STAT contains “blatant factual inaccuracies” and omits critical information about hospital and health systems’…
Headline
The Health Resources and Services Administration yesterday released another $450 million in American Rescue Plan Act payments to rural health care providers to…
Headline
AHA today launched a new suite of resources for rural health care leaders, including an on-demand webinar and playbook. The webinar features rural hospital…
Headline
Join the AHA April 28 at 2 p.m. ET for a discussion with rural hospital leaders and board members on caring for patients during the COVID-19 pandemic, building…
Headline
The Coalition to Protect America’s Health Care, of which the AHA is a founding member, today launched a national television ad urging Congress to reverse…